Search results for "PATIENT"

showing 10 items of 5265 documents

Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: A systematic review with…

2020

Contains fulltext : 229471.pdf (Publisher’s version ) (Closed access) OBJECTIVES: To summarize the available evidence on the diagnostic performance for invasive aspergillosis (IA) in non-hematological, non-solid organ transplantation critically ill patients of the following: (i) existing definitions of IA (developed either for classical immunocompromised populations or for non-immunocompromised critically ill patients); (ii) laboratory tests; (iii) radiology tests. METHODS: A systematic review was performed by evaluating studies assessing the diagnostic performance for IA of a definition/s and/or laboratory/radiology test/s vs. a reference standard (histology) or a reference definition. RES…

0301 basic medicineMicrobiology (medical)Adultmedicine.medical_specialtyCritical Illness030106 microbiologyAspergillosisSensitivity and SpecificityOrgan transplantationMannans03 medical and health sciencesGalactomannanchemistry.chemical_compound0302 clinical medicineDiagnosisMedicineHumansAspergillosis030212 general & internal medicineIntensive care medicineInvasive Pulmonary AspergillosisAdult patientsmedicine.diagnostic_testbusiness.industryCritically illIABiomarkerInvasive pulmonary aspergillosismedicine.diseaseAspergillulnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Infectious DiseasesBronchoalveolar lavageAspergilluschemistryIPAAspergillus; Biomarker; Diagnosis; IA; IPA; Invasive aspergillosis; Adult; Bronchoalveolar Lavage Fluid; Critical Illness; Humans; Mannans; Sensitivity and Specificity; Aspergillosis; Invasive Pulmonary AspergillosisBiomarker (medicine)Aspergillus; Biomarker; Diagnosis; IA; Invasive aspergillosis; IPA; Adult; Bronchoalveolar Lavage Fluid; Critical Illness; Humans; Mannans; Sensitivity and Specificity; Aspergillosis; Invasive Pulmonary AspergillosisInvasive aspergillosisbusinessBronchoalveolar Lavage FluidDiagnosi
researchProduct

Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy

2020

Chronic hepatitis B virus (HBV) infection may be reactivated by immunosuppressive drugs in patients with autoimmune inflammatory rheumatic diseases. This study evaluates HBV serum markers&rsquo

0301 basic medicineMicrobiology (medical)HBsAgmedicine.medical_specialtyimmunosuppressive therapyHbv markersmedicine.disease_causeMicrobiologyGastroenterologyArticleVirus03 medical and health sciences0302 clinical medicineVirologyInternal medicinemedicineIn patientlcsh:QH301-705.5Hepatitis B virusbusiness.industryrheumatic patientsvirus diseasesHBV vaccineHBV markersmedicine.diseaseConnective tissue diseasedigestive system diseasesVaccinationTiter030104 developmental biologylcsh:Biology (General)030211 gastroenterology & hepatologybusinessHBV markers; HBV vaccine; immunosuppressive therapy; rheumatic patientsMicroorganisms
researchProduct

Resistance to third-generation cephalosporins in Escherichia coli in the French community: The times they are a-changin'?

2020

Since the early 2000s, Escherichia coli resistance to third-generation cephalosporins (3GCs) has been increasing in all European countries, mainly due to the spread of extended spectrum β-lactamases (ESBLs). Here we present a retrospective study that combines resistance of E. coli to 3GCs and quinolones with data on antibiotic use in the community in a region of Northeastern France.Since 2012, an observational surveillance of antimicrobial resistance and antibiotic use in the community was conducted: data on antimicrobial resistance in E. coli isolates were collected from 11 private laboratories, and consumption data were collected from the three main healthcare insurances.A significant dec…

0301 basic medicineMicrobiology (medical)Veterinary medicinemedicine.drug_classeducationResistance030106 microbiologyCephalosporinAntibioticsContext (language use)Microbial Sensitivity TestsQuinolonesmedicine.disease_causebeta-LactamasesThird generation cephalosporins03 medical and health sciencesNalidixic Acid0302 clinical medicineAntibiotic resistanceCiprofloxacinDrug Resistance BacterialOutpatientsmedicineEscherichia coliPrevalenceHumansPharmacology (medical)030212 general & internal medicineAntibiotic useEscherichia coliComputingMilieux_MISCELLANEOUSEscherichia coli InfectionsRetrospective StudiesResistance (ecology)business.industryThird-generation cephalosporinsGeneral Medicine3. Good healthAnti-Bacterial AgentsCephalosporins[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious Diseases[SDE]Environmental SciencesFrancebusinessInternational journal of antimicrobial agents
researchProduct

Detection of plasmid-mediated colistin resistance, mcr-1 gene, in Escherichia coli isolated from high-risk patients with acute leukemia in Spain

2019

Background: Bacterial infections in immunocompromised patients are associated with a high mortality and morbidity rate. In this high-risk group, the presence of multidrug-resistant (MDR) bacteria, particularly bacteria that harbor a transferable antibiotic resistance gene, complicates the management of bacterial infections. In this study, we investigated the presence of the transferable colistin resistance mcr genes in patients with leukemia in Spain. Methods: 217 fecal samples collected in 2013-2015 from 56 patients with acute leukemia and colonized with MDR Enterobacteriaceae strains, were screened on September 2017 for the presence of the colistin resistance mcr genes (mcr-1 to -5) by mu…

0301 basic medicineMicrobiology (medical)medicine.drug_class030106 microbiologyAntibioticsColistin resistanceMicrobial Sensitivity TestsBiologymedicine.disease_causebeta-LactamasesMicrobiologyLeukemic patients03 medical and health sciencesMinimum inhibitory concentration0302 clinical medicinePlasmid[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesDrug Resistance BacterialmedicineEscherichia coliHumansPharmacology (medical)[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology030212 general & internal medicineEscherichia coliEscherichia coli Infections[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseasesLeukemiaColistinEscherichia coli ProteinsMiddle Agedbiology.organism_classificationEnterobacteriaceae[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology3. Good healthAnti-Bacterial AgentsInfectious DiseasesSpainColistin resistance Escherichia coli Leukemic patients Spain mcr-1 gene[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyColistinMultilocus sequence typingmcr-1 geneMCR-1hormones hormone substitutes and hormone antagonistsmedicine.drugPlasmids
researchProduct

Influenza vaccination of healthcare workers in Italy: could mandatory vaccination be a solution to protect patients?

2019

Several studies have reported that influenza infections in healthcare workers (HCWs) can lead to nosocomial outbreaks. HCWs can potentially be infected with influenza every year, and may continue to work, encouraging the spread of the virus. Different strategies, such as informative interventions on influenza and influenza vaccination, ‘onsite’ vaccination weeks, communicative strategies through dedicated web and social media pages, and mandatory informed dissent form, were organized for HCWs working at the University Hospital of Palermo, during previous influenza seasons. However, the increased vaccination rates observed among HCWs still remain far from the 75% recommended by Public Healt…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyVaccination CoverageAttitude of Health Personnelhealth care facilities manpower and servicesHealth Personneleducation030106 microbiologyPsychological interventionMandatory ProgramsSettore MED/42 - Igiene Generale E ApplicataMicrobiologyInfectious Disease Transmission Professional-to-PatientHospitals University03 medical and health sciencesHealth careInfluenza HumanmedicineHumansNosocomial outbreakbusiness.industryPublic healthVaccinationvirus diseasesUniversity hospitalMandatory vaccinationcommunication strategies healthcare workers influenza disease perception influenza vaccination mandatory vaccinationVaccination030104 developmental biologyItalyInfluenza VaccinesFamily medicinebusinessFuture microbiology
researchProduct

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

2020

Background: Immune-checkpoint inhibitors have radically changed the treatment landscape of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whether specific clinical characteristics might identify those patients benefiting from immunotherapy more than others. The aim of this study was to identify clinical characteristics associated with disease-specific survival (DSS), time-to-treatment failure (TTF), objective responses (OR) and progressive disease (PD) in NSCLC patients treated with Nivolumab. Methods: This was a multicenter retrospective study conducted on 294 patients treated with Nivolumab for advanced NSCLC. Results: Of the more than 50 variables analyzed, five showed a signifi…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentClinical BiochemistryKaplan-Meier EstimateDisease-Free SurvivalDrug Administration ScheduleNO03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungDrug DiscoverymedicineMalignant pleural effusionHumansimmunotherapy; malignant pleural effusion; nivolumab; non-small-cell lung cancerIn patientmalignant pleural effusionLung cancerImmune Checkpoint InhibitorsRetrospective StudiesPharmacologynivolumabbusiness.industryBrain NeoplasmsLiver NeoplasmsImmunotherapymedicine.diseasePrognosisPleural Effusion Malignantrespiratory tract diseases030104 developmental biologyTreatment Outcomenon-small-cell lung cancer030220 oncology & carcinogenesisFemalesense organsNon small cellimmunotherapyNivolumabbusiness
researchProduct

Predictive factors of response to mTOR inhibitors in neuroendocrine tumours

2016

Medical treatment of neuroendocrine tumours (NETs) has drawn a lot of attention due to the recent demonstration of efficacy of several drugs on progression-free survival, including somatostatin analogs, small tyrosine kinase inhibitors and mTOR inhibitors (or rapalogs). The latter are approved as therapeutic agents in advanced pancreatic NETs and have been demonstrated to be effective in different types of NETs, with variable efficacy due to the development of resistance to treatment. Early detection of patients that may benefit from rapalogs treatment is of paramount importance in order to select the better treatment and avoid ineffective and expensive treatments. Predictive markers for th…

0301 basic medicineOncologyCancer ResearchmTOR inhibitorEndocrinology Diabetes and MetabolismNeuroendocrine tumorsAntineoplastic Agent0302 clinical medicineEndocrinologyNeuroendocrine tumoursneuroendocrine tumourTreatment resistanceMTOR inhibitorsTumorMedical treatmentTOR Serine-Threonine KinasesDiscovery and development of mTOR inhibitorsResponse to treatmentPatient managementDiabetes and MetabolismNeuroendocrine TumorsOncology030220 oncology & carcinogenesisResponse to treatmentNeuroendocrine TumorHumanMTOR inhibitors; Neuroendocrine tumours; Predictors; Response to treatment; Animals; Antineoplastic Agents; Biomarkers Tumor; Diagnostic Imaging; Humans; Neuroendocrine Tumors; Protein Kinase Inhibitors; TOR Serine-Threonine Kinases; Endocrinology Diabetes and Metabolism; Oncology; Endocrinology; Cancer ResearchDiagnostic Imagingmedicine.medical_specialtyProtein Kinase InhibitorEarly detectionpredictorAntineoplastic AgentsMTOR inhibitors; Neuroendocrine tumours; Predictors; Response to treatment; Endocrinology; Oncology; Cancer Research; Endocrinology Diabetes and MetabolismBiologyNO03 medical and health sciencesmTOR inhibitors; neuroendocrine tumours; predictors; response to treatment; Animals; Antineoplastic Agents; Biomarkers Tumor; Diagnostic Imaging; Humans; Neuroendocrine Tumors; Protein Kinase Inhibitors; TOR Serine-Threonine KinasesInternal medicineBiomarkers TumormedicineAnimalsHumansmTOR inhibitorsneuroendocrine tumourspredictorsresponse to treatmentProtein Kinase InhibitorsmTOR inhibitors neuroendocrine tumours predictors response to treatmentAnimalPredictorsmedicine.disease030104 developmental biologyImmunologyBiomarkersResource utilizationEndocrine-Related Cancer
researchProduct

Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in pat…

2017

3539 Background: VEGF-A and ANG-2 have complementary roles in regulation of tumor angiogenesis. Targeting VEGF-A with BEV in combination chemotherapy (CT) in mCRC has proven to increase PFS and OS. ANG-2 is overexpressed and associated with poor outcome of mCRC pts receiving BEVcontaining treatment. Hence, dual blockade of VEGF-A and ANG-2 by the bispecific mAb VAN with standard CT may improve clinical activity in mCRC. Methods: All pts received mFOLFOX-6 and were randomized 1:1 to also receive intravenous VAN 2000 mg every other week (Q2W) (Arm A) or BEV 5 mg/kg Q2W (Arm B). The primary end point was investigator assessed progression-free survival (PFS). Key eligibility criteria included …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerbusiness.industryPhases of clinical researchCombination chemotherapymedicine.diseaseSurgeryDouble blind03 medical and health sciences030104 developmental biologyOncologyFOLFOXVanucizumabInternal medicinemedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

The Quality Oncology Practice Initiative program: Experience in Spain.

2017

214 Background: Patient care quality is a discipline that is being considered highly important in today’s healthcare. Quality Oncology Practice Initiative (QOPI) is a referral worldwide in terms of quality for oncology practices. The ECO Foundation is a platform of experts representing the major Spanish hospitals involved in the treatment of cancer patients. ECO reached an agreement with QOPI in order to involve Spanish hospitals in the participation of the QOPI program. Methods: Two rounds of data collection were carried out (Fall 2015 and Spring 2016). Practices had to registered on-line and submit data into the platform provided by QOPI. ECO Foundation offers all centres the support of …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyData collectionReferralbusiness.industrymedia_common.quotation_subjectPatient care03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineFamily medicineHealth caremedicineQuality (business)businessmedia_commonJournal of Clinical Oncology
researchProduct

HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women

2020

Background: Breast cancer in very young women (BCVY) defined as &lt

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyDose dependencelcsh:RC254-282ArticleLMK-23503 medical and health sciences0302 clinical medicineBreast cancerbreast cancerOlder patientsInternal medicinemedicineskin and connective tissue diseasesPathologicalHDAC5 inhibitorsHistone deacetylase 5young womenbusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncologyApoptosisCell culture030220 oncology & carcinogenesishistone deacetylaseHistone deacetylasebusiness
researchProduct